Login / Signup

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.

Tadahiro ShojiShunsuke TatsukiMarina AbeHidetoshi TomabechiEriko TakatoriYoshitaka KaidoTakayuki NagasawaMasahiro KagabuTsukasa BabaHiroaki Itamochi
Published in: Cancers (2021)
Ovarian cancer has the worst prognosis among gynecological cancers. In particular, clear cell and mucinous carcinomas are less sensitive to chemotherapy. The establishment of new therapies is necessary to improve the treatment outcomes for these carcinomas. In previous clinical studies, chemotherapy with cytotoxic anticancer drugs has failed to demonstrate better treatment outcomes than paclitaxel + carboplatin therapy. In recent years, attention has been focused on treatment with molecular target drugs and immune checkpoint inhibitors that target newly identified biomarkers. The issues that need to be addressed include the most appropriate combination of therapies, identifying patients who may benefit from each therapy, and how results should be incorporated into the standard of care for ovarian clear cell and mucinous carcinomas. In this article, we have reviewed the most promising therapies for ovarian clear cell and mucinous carcinomas, which are regarded as intractable, with an emphasis on therapies currently being investigated in clinical studies.
Keyphrases
  • clear cell
  • high grade
  • low grade
  • healthcare
  • palliative care
  • squamous cell carcinoma
  • mass spectrometry
  • chemotherapy induced
  • mesenchymal stem cells
  • chronic pain
  • cell therapy